Position in JNJ
as of Jun 30, 2026
· filed Aug 11, 2026
Position Value
$1,308,707
+$49,108 QoQ
Shares Held
5,153
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.12%
of 13F equity value
Holder Rank
#2,730
of 4,664 holders
Holding Since
Dec 2023
11 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in JNJ Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026FOSTER DYKEMA CABOT & PARTNERS, LLC holds $37,893,315 across 11 Drug Manufacturers - General names. JNJ ranks #2 (3.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
28,025 | $33,614,028 | |
| 2 | JNJ |
Johnson & Johnson
This page
|
5,153 | $1,308,707 | |
| 3 | MRK |
Merck & Co., Inc.
|
8,626 | $1,108,441 | |
| 4 | ABBV |
AbbVie Inc.
|
3,815 | $960,006 | |
| 5 | NVO |
Novo Nordisk A S
|
4,526 | $216,976 | |
| 6 | NVS |
Novartis AG
|
1,094 | $171,451 | |
| 7 | AZN |
Astrazeneca PLC
|
820 | $155,488 | |
| 8 | AMGN |
Amgen Inc
|
420 | $152,090 |
All Filings in JNJ
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,308,707 | 5,153 | Shares | Sole | 2026-08-11 | |
| 2026-03-31 | $1,259,599 | 5,153 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $1,066,413 | 5,153 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $1,189,283 | 6,414 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $841,958 | 5,512 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $781,438 | 4,712 | Shares | Sole | 2025-05-09 | |
| 2024-12-31 | $740,599 | 5,121 | Shares | Sole | 2025-02-13 | |
| 2024-09-30 | $927,631 | 5,724 | Shares | Sole | 2024-11-12 | |
| 2024-06-30 | $703,321 | 4,812 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | $724,826 | 4,582 | Shares | Sole | 2024-05-10 | |
| 2023-12-31 | $714,264 | 4,557 | Shares | Sole | 2024-02-14 | |
| No filing history on record for this holder in this stock. | ||||||